The goal of this clinical trial is to:
* In Phase 1 (observational) to develop an algorithm for treatment of Duffy-null positive patients for chemotherapy dosing * In Phase 2 (interventional), use the algorithm created in phase 1 to adjust chemotherapy dosing for Duffy-null patients
Participant must self-identify as being of Middle Eastern or African descent.
Participant must be diagnosed with histologically or cytologically confirmed solid organ cancer and be treatment naive.
Melanoma is allowed; sarcoma is not eligible.
Secondary malignancies are allowed.
Participants with active and uncontrolled bacterial, viral, or fungal infection requiring IV antibiotics.
Participants who have ever received cytotoxic chemotherapy.
Participants who are receiving concurrent chemo-radiation treatment.
Participants who are taking any other investigational drugs.